Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients

References

• Aschenbrenner DS. Drug watch. Am J Nurs 2006;106:29-31
   Google Scholar
• Joseph JJ, Pillai A, Bramley D. Clopidogrel in orthopaedic patients: a review of current practice in Scotland. Thromb J 2007;5:6
   PubMedGoogle Scholar
• Top 15 Global Products, 2009, Total Audited Markets. IMS Heath Reports. New Jersey, US: IMS Health, 2009. Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Top%2015%20Global%20Products_2009.pdf [Last accessed 16 February 2012]
   Google Scholar
• Gurbel PA, Tantry US, Kereiakes DJ. Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. Drug Healthc Patient Saf 2010;2:233-40
   Google Scholar
• Harjai KJ, Shenoy C, Orshaw P, et al. Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Circ Cardiovasc Interv 2011;4:162-70
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60
   PubMed Web of Science ®Google Scholar
• Li XQ, Andersson TB, Ahlström M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-7
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet 2009;374:989-97
   PubMed Web of Science ®Google Scholar
• Gupta E, Bansal D, Sotos J, et al. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci 2010;55:1964-8
   PubMed Web of Science ®Google Scholar
• Ho PM, Maddox TM, Wing L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44
   PubMed Web of Science ®Google Scholar
• Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the Clopidogrel Medco Outcomes Study. Pharmacotherapy 2010;30:787-96
   PubMed Web of Science ®Google Scholar
• Tsai Y, Wen Y, Huang W, et al. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. J Gastroenterol 2011;46:39-45
   PubMed Web of Science ®Google Scholar
• Van Boxel OS, Van Oijen MGH, Hagenaars MP, et al. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol 2010;105:2430-6
   PubMed Web of Science ®Google Scholar
• Yasuda H, Yamada M, Sawada S, et al. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting. Intern Med 2009;48:1725-30
   PubMed Web of Science ®Google Scholar
• Bhurke SM, Martin BC, Li C, et al. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy 2012;32:809-18
   PubMed Web of Science ®Google Scholar
• Clopidogrel (marketed as Plavix) and Omeprazole (marketed as Prilosec) – drug interaction. FDA Safety Information. Washingon, DC: US Food and Drug Administration, 2009. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190848.htm [Last accessed 8 December 2011]
   Google Scholar
• Public statement on possible interaction between clopidogrel and proton pump inhibitors. London: European Medicines Agency, 2009. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf [Last accessed 12 April 2012]
   Google Scholar
• Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors. Ann Intern Med 2010;152:337-45
   PubMed Web of Science ®Google Scholar
• Schmidt M, Johansen MB, Robertson DJ, et al. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther 2011;35:165-74
   PubMed Web of Science ®Google Scholar
• Hsiao FY, Mullins CD, Wen YW, et al. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. Pharmacoepidemiol Drug Saf 2011;20:1043-9
   PubMed Web of Science ®Google Scholar
• Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010;153:378-86
   PubMed Web of Science ®Google Scholar
• Tentzeris I, Jarai R, Farhan S, et al. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost 2010;104:1211-18
   PubMed Web of Science ®Google Scholar
• Rossini R, Capodanno D, Musumeci G, et al. Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. Coron Artery Dis 2011;22:199-205
   PubMed Web of Science ®Google Scholar
• Cardiovascular disease risk factors. Geneva: World Heart Federation. Available at: http://www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors/[Last accessed 4 December 2011]
   Google Scholar
• Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 2003;48:133-43
   PubMed Web of Science ®Google Scholar
• Wynne HA, James OFW. The ageing liver. Age Ageing 1990;19:1-3
   PubMed Web of Science ®Google Scholar
• Nikolsky E, Stone GW, Kirtane AJ, et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009;54:1293-302
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011;171:998-1004
   PubMed Web of Science ®Google Scholar
• Ng FH, Tunggal P, Chu WM. Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. Am J Gastroenterol 2012;107:389-96
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-18
   PubMed Web of Science ®Google Scholar
• Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009;120:2322-9
   PubMed Web of Science ®Google Scholar
• Sørensen R, Gislason GH, Fosbøl EL, et al. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol 2008;66:875-84
   PubMed Web of Science ®Google Scholar
• Rao SV, Kaltenbach LA, Weintraub WS, et al. Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. JAMA 2011;306:1461-7
   PubMed Web of Science ®Google Scholar
• Kiyota Y, Schneeweiss S, Glynn RJ, et al. The accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value based on review of hospital records. Am Heart J 2004;148:99-104
   PubMed Web of Science ®Google Scholar
• Reker DM, Hamilton BB, Duncan PW, et al. Stroke: Who’s counting what? J Rehabil Res Dev 2001;38:281-9
   PubMed Web of Science ®Google Scholar
• Harmsze AM, van Werkum JW, Moral F, et al. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets 2011;22:98-102
   PubMed Web of Science ®Google Scholar
• D’Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Method Inform Med 1993;32:382-7
   PubMed Web of Science ®Google Scholar
• Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Disp 2004;32:821-7
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose. The PACA (Proton Pump Inhibitors and clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009;54:1149-53
   PubMed Web of Science ®Google Scholar
• Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714-19
   PubMed Web of Science ®Google Scholar
• Neubauer H, Engelhardt A, Kruger JC, et al. Pantoprazole does not influence the antiplatelet effect of clopiodgrel: a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol 2010;56:91-7
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantopraole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148.e1-5
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011;89:65-74
   PubMed Web of Science ®Google Scholar
• Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010;170:704-10
   PubMed Web of Science ®Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16
   PubMed Web of Science ®Google Scholar
• Tran M, Tafreshi J, Pai RG. Combination of clopidogrel and proton pump inhibitors: implications for clinicians. J Cardiovasc Pharmacol Ther 2010;15:326-37
   PubMed Web of Science ®Google Scholar